163 related articles for article (PubMed ID: 35541758)
1. Egress and invasion machinery of malaria: an in-depth look into the structural and functional features of the flap dynamics of plasmepsin IX and X.
Munsamy G; Ramharack P; Soliman MES
RSC Adv; 2018 Jun; 8(39):21829-21840. PubMed ID: 35541758
[TBL] [Abstract][Full Text] [Related]
2. Flap flexibility amongst plasmepsins I, II, III, IV, and V: Sequence, structural, and molecular dynamics analyses.
McGillewie L; Soliman ME
Proteins; 2015 Sep; 83(9):1693-705. PubMed ID: 26146842
[TBL] [Abstract][Full Text] [Related]
3. A dual target of Plasmepsin IX and X: Unveiling the atomistic superiority of a core chemical scaffold in malaria therapy.
Munsamy G; Agoni C; Soliman MES
J Cell Biochem; 2019 May; 120(5):7876-7887. PubMed ID: 30430636
[TBL] [Abstract][Full Text] [Related]
4. The binding landscape of plasmepsin V and the implications for flap dynamics.
L M; Soliman ME
Mol Biosyst; 2016 Apr; 12(5):1457-67. PubMed ID: 26965894
[TBL] [Abstract][Full Text] [Related]
5. Exploiting Structural Dynamics To Design Open-Flap Inhibitors of Malarial Aspartic Proteases.
Bobrovs R; Jaudzems K; Jirgensons A
J Med Chem; 2019 Oct; 62(20):8931-8950. PubMed ID: 31062983
[TBL] [Abstract][Full Text] [Related]
6. Predicting functional residues in Plasmodium falciparum plasmepsins by combining sequence and structural analysis with molecular dynamics simulations.
Valiente PA; Batista PR; Pupo A; Pons T; Valencia A; Pascutti PG
Proteins; 2008 Nov; 73(2):440-57. PubMed ID: 18442137
[TBL] [Abstract][Full Text] [Related]
7. Azole-based non-peptidomimetic plasmepsin inhibitors.
Kinena L; Leitis G; Kanepe-Lapsa I; Bobrovs R; Jaudzems K; Ozola V; Suna E; Jirgensons A
Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800151. PubMed ID: 30063266
[TBL] [Abstract][Full Text] [Related]
8. Plasmepsins as potential targets for new antimalarial therapy.
Ersmark K; Samuelsson B; Hallberg A
Med Res Rev; 2006 Sep; 26(5):626-66. PubMed ID: 16838300
[TBL] [Abstract][Full Text] [Related]
9. Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D.
Zogota R; Kinena L; Withers-Martinez C; Blackman MJ; Bobrovs R; Pantelejevs T; Kanepe-Lapsa I; Ozola V; Jaudzems K; Suna E; Jirgensons A
Eur J Med Chem; 2019 Feb; 163():344-352. PubMed ID: 30529637
[TBL] [Abstract][Full Text] [Related]
10. Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax.
Hodder AN; Christensen J; Scally S; Triglia T; Ngo A; Birkinshaw RW; Bailey B; Favuzza P; Dietrich MH; Tham WH; Czabotar PE; Lowes K; Guo Z; Murgolo N; Lera Ruiz M; McCauley JA; Sleebs BE; Olsen D; Cowman AF
Structure; 2022 Jul; 30(7):947-961.e6. PubMed ID: 35460613
[TBL] [Abstract][Full Text] [Related]
11. Unveiling a New Era in Malaria Therapeutics: A Tailored Molecular Approach Towards the Design of Plasmepsin IX Inhibitors.
Munsamy G; Soliman MES
Protein J; 2019 Dec; 38(6):616-627. PubMed ID: 31586296
[TBL] [Abstract][Full Text] [Related]
12. Plasmodium falciparum ookinete expression of plasmepsin VII and plasmepsin X.
Li F; Bounkeua V; Pettersen K; Vinetz JM
Malar J; 2016 Feb; 15():111. PubMed ID: 26911483
[TBL] [Abstract][Full Text] [Related]
13. Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion.
Nasamu AS; Glushakova S; Russo I; Vaupel B; Oksman A; Kim AS; Fremont DH; Tolia N; Beck JR; Meyers MJ; Niles JC; Zimmerberg J; Goldberg DE
Science; 2017 Oct; 358(6362):518-522. PubMed ID: 29074774
[TBL] [Abstract][Full Text] [Related]
14. Fighting malaria: structure-guided discovery of nonpeptidomimetic plasmepsin inhibitors.
Huizing AP; Mondal M; Hirsch AK
J Med Chem; 2015 Jul; 58(13):5151-63. PubMed ID: 25719272
[TBL] [Abstract][Full Text] [Related]
15. A target safety assessment of the potential toxicological risks of targeting plasmepsin IX/X for the treatment of malaria.
Barber J; Sikakana P; Sadler C; Baud D; Valentin JP; Roberts R
Toxicol Res (Camb); 2021 Mar; 10(2):203-213. PubMed ID: 33884171
[TBL] [Abstract][Full Text] [Related]
16. Antimalarials: Review of Plasmepsins as Drug Targets and HIV Protease Inhibitors Interactions.
Miller Iii WA; Teye J; Achieng AO; Mogire RM; Akala H; Ong'echa JM; Rathi B; Durvasula R; Kempaiah P; Kwofie SK
Curr Top Med Chem; 2019; 18(23):2022-2028. PubMed ID: 30499404
[TBL] [Abstract][Full Text] [Related]
17. Pyrrolidine derivatives as plasmepsin inhibitors: binding mode analysis assisted by molecular dynamics simulations of a highly flexible protein.
Luksch T; Blum A; Klee N; Diederich WE; Sotriffer CA; Klebe G
ChemMedChem; 2010 Mar; 5(3):443-54. PubMed ID: 20112327
[TBL] [Abstract][Full Text] [Related]
18. Flap dynamics of plasmepsin proteases: insight into proposed parameters and molecular dynamics.
Karubiu W; Bhakat S; McGillewie L; Soliman ME
Mol Biosyst; 2015 Apr; 11(4):1061-6. PubMed ID: 25630418
[TBL] [Abstract][Full Text] [Related]
19. Exploring the pH- and Ligand-Dependent Flap Dynamics of Malarial Plasmepsin II.
Henderson JA; Shen J
J Chem Inf Model; 2022 Jan; 62(1):150-158. PubMed ID: 34964641
[TBL] [Abstract][Full Text] [Related]
20. Flap Dynamics in Pepsin-Like Aspartic Proteases: A Computational Perspective Using Plasmepsin-II and BACE-1 as Model Systems.
Bhakat S; Söderhjelm P
J Chem Inf Model; 2022 Feb; 62(4):914-926. PubMed ID: 35138093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
